Literature DB >> 21948370

Nuclear factor-κB in immunity and inflammation: the Treg and Th17 connection.

Qingguo Ruan1, Youhai H Chen.   

Abstract

Although nuclear factor-kB (NF-kB) is generally considered to be a pro-inflammatory transcription factor, recent studies indicate that it also plays a critical role in the development of an anti-inflammatory T cell subset called regulatory T (Treg) cells. Two NF-kB proteins, c-Rel and p65, drive the development of Treg cells by promoting the formation of a Foxp3-specific enhanceosome. Consequently, c-Rel-deficient mice have marked reductions in Treg cells, and c-Rel-deficient T cells are compromised in Treg cell differentiation. However, with the exception of Foxp3, most NF-kB target genes in immune cells are pro-inflammatory. These include several Th17-related cytokine genes and the retinoid-related orphan receptor-g (Rorg or Rorc) that specifies Th17 differentiation and lineage-specific function. T cells deficient in c-Rel or p65 are significantly compromised in Th17 differentiation, and c-Rel -deficient mice are defective in Th17 responses. Thus, NF-kB is required for the development of both anti-inflammatory Treg and pro-inflammatory Th17 cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21948370     DOI: 10.1007/978-1-4614-0106-3_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  23 in total

Review 1.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

2.  p(⁷⁰S⁶K¹) in the TORC1 pathway is essential for the differentiation of Th17 Cells, but not Th1, Th2, or Treg cells in mice.

Authors:  Carl Y Sasaki; Gang Chen; Rachel Munk; Erez Eitan; Jennifer Martindale; Dan L Longo; Paritosh Ghosh
Journal:  Eur J Immunol       Date:  2015-11-19       Impact factor: 5.532

3.  MicroRNA-125b regulates Th17/Treg cell differentiation and is associated with juvenile idiopathic arthritis.

Authors:  Zhi-Dan Fan; Qian Cao; Na Huang; Le Ma; Hui-Hui Ma; Ya-Yuan Zhang; Hai-Guo Yu; Guo-Ping Zhou
Journal:  World J Pediatr       Date:  2019-05-17       Impact factor: 2.764

4.  miR-455-5p downregulation promotes inflammation pathways in the relapse phase of relapsing-remitting multiple sclerosis disease.

Authors:  Shukoofeh Torabi; Mona Tamaddon; Mojtaba Asadolahi; Gelareh Shokri; Rezvan Tavakoli; Nooshin Tasharrofi; Reza Rezaei; Vahid Tavakolpour; Hossein Sazegar; Fatemeh Kouhkan
Journal:  Immunogenetics       Date:  2018-10-11       Impact factor: 2.846

5.  A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.

Authors:  Yusuke Shono; Andrea Z Tuckett; Samedy Ouk; Hsiou-Chi Liou; Grégoire Altan-Bonnet; Jennifer J Tsai; Jennifer E Oyler; Odette M Smith; Mallory L West; Natalie V Singer; Ekaterina Doubrovina; Dmitry Pankov; Chandresh V Undhad; George F Murphy; Cecilia Lezcano; Chen Liu; Richard J O'Reilly; Marcel R M van den Brink; Johannes L Zakrzewski
Journal:  Cancer Discov       Date:  2014-02-18       Impact factor: 39.397

6.  c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice.

Authors:  Yu Yu; Dapeng Wang; Kane Kaosaard; Chen Liu; Jianing Fu; Kelley Haarberg; Claudio Anasetti; Amer A Beg; Xue-Zhong Yu
Journal:  Eur J Immunol       Date:  2013-07-04       Impact factor: 5.532

7.  A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy.

Authors:  Lena F Schimke; Nikolaus Rieber; Stacey Rylaarsdam; Otávio Cabral-Marques; Nicholas Hubbard; Anne Puel; Laura Kallmann; Stephanie Anover Sombke; Gundula Notheis; Hans-Peter Schwarz; Birgit Kammer; Tomas Hökfelt; Reinald Repp; Capucine Picard; Jean-Laurent Casanova; Bernd H Belohradsky; Michael H Albert; Hans D Ochs; Ellen D Renner; Troy R Torgerson
Journal:  J Clin Immunol       Date:  2013-05-25       Impact factor: 8.317

Review 8.  TCR signaling to NF-κB and mTORC1: Expanding roles of the CARMA1 complex.

Authors:  Jian-hong Shi; Shao-Cong Sun
Journal:  Mol Immunol       Date:  2015-08-08       Impact factor: 4.407

9.  Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.

Authors:  Eric R Lutz; Annie A Wu; Elaine Bigelow; Rajni Sharma; Guanglan Mo; Kevin Soares; Sara Solt; Alvin Dorman; Anthony Wamwea; Allison Yager; Daniel Laheru; Christopher L Wolfgang; Jiang Wang; Ralph H Hruban; Robert A Anders; Elizabeth M Jaffee; Lei Zheng
Journal:  Cancer Immunol Res       Date:  2014-06-18       Impact factor: 11.151

10.  Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.

Authors:  Scott Best; Vi Lam; Tingting Liu; Nur Bruss; Adam Kittai; Olga V Danilova; Susan Murray; Allison Berger; Nathan D Pennock; Evan F Lind; Alexey V Danilov
Journal:  Leukemia       Date:  2020-03-16       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.